Recursion Pharmaceuticals (RXRX) Other financing activities (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has 6 years of Other financing activities data on file, last reported at $793000.0 in Q4 2025.

• Quarterly Other financing activities fell 53.63% year-over-year to $793000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.1 million (down 49.74% YoY) and the FY2025 annual result came in at $4.1 million, down 49.74% from the prior year.
• Other financing activities improved to $793000.0 in Q4 2025, from -$993000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $460.7 million in Q2 2021 to a low of -$458.3 million in Q3 2021.
• A 5-year average of $2.2 million and a median of $2.3 million in 2021 frame the typical range for Other financing activities.
• The widest YoY moves for Other financing activities: up 2879768.75% in 2021, down 201985.9% in 2021.
• Tracing RXRX's Other financing activities over 5 years: stood at $3.8 million in 2021, then dropped by 6.52% to $3.6 million in 2022, then declined by 8.63% to $3.3 million in 2023, then slumped by 47.55% to $1.7 million in 2024, then plunged by 53.63% to $793000.0 in 2025.
• The last three Other financing activities figures came in at $793000.0 (Q4 2025), -$993000.0 (Q3 2025), and $2.7 million (Q2 2025), per Business Quant data.